1. MicroRNA Machinery Genes as Novel Biomarkers for Cancer
   Jing-Tao Huang et al, 2014, Front. Oncol. CrossRef
2. Prognostic significance of Dicer expression in hepatocellular carcinoma.
   L I Zhang et al, 2016, Oncol Lett CrossRef
3. VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin
   RUCHENG YAO et al, 2014 CrossRef
4. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1
   Yanan Wang et al, 2018, Cell Death Dis CrossRef
5. Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs
   Bernhard Biersack, 2017, Non-coding RNA Research CrossRef
6. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells
   Hui-Huang Lai et al, 2018, Biochemical and Biophysical Research Communications CrossRef
7. null
   Rong Guo et al, 2014 CrossRef
8. Mutant p53 Regulates Dicer through p63-dependent and -independent Mechanisms to Promote an Invasive Phenotype
   Patricia A. J. Muller et al, 2014, J. Biol. Chem. CrossRef
9. A low dicer expression is associated with resistance to 5-FU-based chemoradiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma
   Kenta Kawahara et al, 2014, J Oral Pathol Med CrossRef
10. Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research
    Angiolo Gadducci et al, 2014, Gynecological Endocrinology CrossRef
11. Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet?
    Viive M. Howell, 2014, Seminars in Cell & Developmental Biology CrossRef
12. RAD001 can reverse drug resistance of SGC7901/DDP cells.
    Liu Ying et al, 0 CrossRef
13. Ovarian Cancer: Interplay of Vitamin D Signaling and miRNA Action
    Rukset Attar et al, 2014, Asian Pacific Journal of Cancer Prevention CrossRef
14. MicroRNAs in cancer: biomarkers, functions and therapy.
    Josie Hayes et al, 2014, Trends Mol Med CrossRef
15. Restoring TRAIL Mediated Signaling in Ovarian Cancer Cells
    Ammad Ahmad Farooqi et al, 2014, Arch. Immunol. Ther. Exp. CrossRef
16. Genomic alterations as mediators of miRNA dysregulation in ovarian cancer
    Casina W. S. Kan et al, 2015, Genes Chromosomes Cancer CrossRef
17. Dicer ablation promotes a mesenchymal and invasive phenotype in bladder cancer cells
    ALAN P. LOMBARD et al, 2015 CrossRef
18. In vitroevaluation of Aurora kinase inhibitor—VX680—in formulation of PLA-TPGS nanoparticles
    Thi Thuy Duong Le et al, 2016, Adv. Nat. Sci: Nanosci. Nanotechnol. CrossRef
19. Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression
    Ying Zhu et al, 2016, Tumor Biol. CrossRef
20. Impaired expression of DICER and some microRNAs in HBZ expressing cells from acute adult T-cell leukemia patients
    Hélène Gazon et al, 2016, Oncotarget CrossRef
21. Dicer affects cisplatin‑mediated apoptosis in epithelial ovarian cancer cells
    Xi Wang et al, 2018, Mol Med Report CrossRef
22. Recent trends in targeting miRNAs for cancer therapy
    Vandit Shah et al, 2020, J Pharm Pharmacol CrossRef
23. MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance
    Milosz Wilczynski et al, 2020, Cancers CrossRef
24. Dicing the Disease with Dicer: The Implications of Dicer Ribonuclease in Human Pathologies
    Eleni I. Theotoki et al, 2020, IJMS CrossRef
25. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma
    Cankun Zhou et al, 2020, Cancer Cell Int CrossRef
26. ERK‐mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer
    Yen‐Hao Su et al, 2020, J Cell Physiol CrossRef
27. miR326 Maturation Is Crucial for VEGF-C–Driven Cortactin Expression and Esophageal Cancer Progression
    Chih-Chen Hong et al, 2014, Cancer Res CrossRef
28. Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL.
    Ting-Yu Chang et al, 2016, Cancer Res CrossRef
29. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
    Bayley A. Jones et al, 2018, Mol Cancer Ther CrossRef
30. Transcriptional suppression of Dicer by HOXB‐AS3/EZH2 complex dictates sorafenib resistance and cancer stemness
    Chi‐Feng Tseng et al, 2022, Cancer Science CrossRef
31. Exosomes and MicroRNAs in Biomedical Science
    Hamed Mirzaei et al, 2022, Synthesis Lectures on Biomedical Engineering CrossRef
32. null
    Hamed Mirzaei et al, 2022 CrossRef
33. The Role of Molecular Genetic Studies in Current Oncology
    Oleg I. Kit et al, 2022, Annals RAMS CrossRef
34. Dicer-mediated miR-200b expression contributes to cell migratory/invasive abilities and cancer stem cells properties of breast cancer cells
    Tung-Wei Hsu et al, 2022, Aging CrossRef
35. EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies
    Ivana Samaržija et al, 2022, Cancers CrossRef
36. Mechanisms of Regulation of the Expression of miRNAs and lncRNAs by Metformin in Ovarian Cancer
    Ignacio Alfaro et al, 2023, Pharmaceuticals CrossRef
37. Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach
    Jingtao Wei et al, 2023, Cell Oncol. CrossRef
38. Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression
    Yu-Wen Yeh et al, 2023, Aging CrossRef